Biophytis Enhances Intellectual Property in Obesity Treatment with New Patent Application

Biophytis SA, a clinical-stage biotechnology firm, announced its latest patent application aimed at reinforcing its obesity treatment prospects through its drug candidate, BIO101. This filing is predicted to bolster patent protection until 2044, enhancing the company's strategic positioning in the lucrative obesity treatment market.

According to Biophytis, the application will strengthen BIO101's potential in combination with GLP-1 RAs, a current treatment mechanism for obesity. This aligns with the drug's promising outcomes in preclinical and ongoing clinical studies, notably the SARA-INT phase 2 study aiming at muscle function preservation in obese patients treated with GLP-1 RAs.

Biophytis CEO, Stanislas Veillet, indicated the addition would complete the company's patent collection for BIO101. This portfolio includes 14 patent families with 42 issued patents and 39 pending worldwide. With the obesity market expected to surge to $100 billion by 2030, the firm is set to capitalize on this growth, provided regulatory approvals are granted.